Completed PHASE3 INTERVENTIONAL 2-arm NCT00744627

Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder

Sponsor: H. Lundbeck A/S

Conditions Generalized Anxiety Disorder

Interventions Placebo Vortioxetine

Updated 6 times since 2017 Last updated: Jan 28, 2014 Started: Sep 30, 2008 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Generalized Anxiety Disorder and is currently completed. H. Lundbeck A/S leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S
Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Saarow, Germany , Berlin, Germany , Bialystok, Poland , Bochum, Germany , Bucharest, Romania , Dnipro, Ukraine , Gdynia, Poland , Gorlice, Poland , Hüttenberg, Germany , Kaunas, Lithuania and 28 more locations